ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,010.60
0.00%
US Tech 100
16,806.40
0.32%
Dow Jones
38,239.98
0.00%
Brent Oil
85.495
-1.06%
Bitcoin
66,160.08
-1.04%
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Merus NV (MRUS) Quote

Merus NV

Merus NV (MRUS)

NASDAQ
40.45
0.64
(1.61%)
Closed April 22 4:00PM
Delayed by 15 minutes
40.45
0.00
( 0.00% )
Pre Market: 7:00AM
Delayed by 15 minutes

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
40.45
Bid
40.45
Ask
50.21
Volume
-
0.00 Day's Range 0.00
18.21 52 Week Range 52.035
Market Cap
-
Previous Close
40.45
Open
-
Last Trade
Last Trade Time
-
Financial Volume
-
VWAP
-
Average Volume (3m)
579,669
Shares Outstanding
57,878,284
Dividend Yield
-
PE Ratio
-
Earnings Per Share (EPS)
-
Revenue
-
Net Profit
-

About Merus NV

Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics. Merus only reportable segment comprising the discovery and development of innovative ... Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics. Merus only reportable segment comprising the discovery and development of innovative bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others. Show more

Sector
Gen Med & Surgical Hospitals
Industry
Gen Med & Surgical Hospitals
Website
www.merus.nl
Headquarters
Utrecht, Utrecht, Nld
Founded
1970
Merus NV is listed in the Gen Med & Surgical Hospitals sector of the NASDAQ with ticker MRUS. The last closing price for Merus NV was $40.45. Over the last year, Merus NV shares have traded in a share price range of $ 18.21 to $ 52.035.

Merus NV currently has 57,878,284 shares outstanding.

MRUS Latest News

More News

Merus Presents Preclinical Data Demonstrating Efficacy of Zeno in Cancer Models with High NRG1 Expression at the AACR Annual Meeting 2024

UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 08, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing...

April 08 2024
GlobeNewswire Inc.

Merus to Participate in a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference

UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific...

April 03 2024
GlobeNewswire Inc.

Form 8-K - Current report

March 06 2024
Edgar (US Regulatory)

Gilead and Merus Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers

– Gilead Receives Exclusive Option to License Novel Trispecific Therapeutics Resulting from the Collaboration – Gilead Sciences, Inc. (Nasdaq:GILD) and Merus N.V. (Nasdaq:MRUS) today announced a...

March 06 2024
Business Wire

Merus Announces Publication of an Abstract for Presentation at the AACR Annual Meeting 2024: Zeno is effective in cancer models with high NRG1 expression

UTRECHT, The Netherlands and CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing...

March 05 2024
GlobeNewswire Inc.

Merus to Participate in a Fireside Chat at the Leerink Partners Global Biopharma Conference

UTRECHT, The Netherlands and CAMBRIDGE, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific...

March 04 2024
GlobeNewswire Inc.

Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers

February 28 2024
Edgar (US Regulatory)

Merus Announces Financial Results for the Fourth Quarter and Full Year 2023 and Provides Business Update

-   Petosemtamab in 1L HNSCC in combination with pembrolizumab initial interim clinical data planned for 2Q24; preparing for a potential phase 3 trial -   Petosemtamab in 2L+ HNSCC phase 3 trial...

February 28 2024
GlobeNewswire Inc.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.66-1.6054487959141.1142.37539.2759471540.32461346CS
4-4.66-10.330303702145.1146.5639.2748897842.73927669CS
125.1314.524348810935.3252.03534.7657966944.1839814CS
2620.3100.74441687320.1552.03519.80551563835.9710585CS
5218.4984.198542805121.9652.03518.2141539130.9562704CS
15616.4968.823038397323.9652.03512.0334757425.80867201CS
26023.62140.34462269816.8352.03510.1824696924.41721058CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
CYNCYNGN Inc
$ 0.24805
(105.00%)
78.88M
PEGYPineapple Energy Inc
$ 0.0679
(48.25%)
73.65M
RGCRegencell Bioscience Holdings Ltd
$ 9.00
(39.75%)
1.46k
HWHHWH International Inc
$ 1.74
(35.94%)
10.3M
PALIPalisade Bio Inc
$ 6.68
(35.50%)
1.42M
GWAVGreenwave Technology Solutions Inc
$ 0.0676
(-46.48%)
6.43M
ABEOAbeona Therapeutics Inc
$ 3.98
(-45.92%)
246.17k
HUGEFSD Pharma Inc
$ 0.4001
(-18.18%)
149
AUIDauthID Inc
$ 6.30
(-18.08%)
9.2k
OCXOncocyte Corporation
$ 2.10
(-16.33%)
311
CYNCYNGN Inc
$ 0.24805
(105.00%)
78.88M
PEGYPineapple Energy Inc
$ 0.0679
(48.25%)
73.65M
HWHHWH International Inc
$ 1.74
(35.94%)
10.3M
JAGXJaguar Health Inc
$ 0.1625
(-9.67%)
7.04M
AGBAAGBA Group Holding Ltd
$ 3.03
(21.20%)
7.01M

MRUS Discussion

View Posts
Phosphene Phosphene 3 years ago
Merus and myTomorrows Announce Expansion of Collaboration for Screening and eNRGy Clinical Trial Awareness for Cancer Patients with Neuregulin 1 Fusion Tumors

https://www.globenewswire.com/news-release/2020/10/12/2107078/0/en/Merus-and-myTomorrows-Announce-Expansion-of-Collaboration-for-Screening-and-eNRGy-Clinical-Trial-Awareness-for-Cancer-Patients-with-Neuregulin-1-Fusion-Tumors.html
👍️0
Phosphene Phosphene 4 years ago
The Baker Brothers have 7% ownership.

https://whalewisdom.com/filer/baker-bros-advisors-llc#tabholdings_tab_link
👍️0
Phosphene Phosphene 4 years ago
Board Member: Victor Sandor

https://ir.merus.nl/board-member/victor-sandor

https://www.businesswire.com/news/home/20200824005127/en/Prelude-Therapeutics-Announces-Closing-50M-Series-Financing
👍️0
Phosphene Phosphene 4 years ago
Second Quarter 2020 Results:

https://www.globenewswire.com/news-release/2020/08/06/2074649/0/en/Merus-Announces-Financial-Results-for-the-Second-Quarter-and-Provides-Business-Update.html
👍️0
Phosphene Phosphene 4 years ago
https://merus.nl/
👍️0
Phosphene Phosphene 4 years ago
European cancer biotech Merus nabs Sanofi I-O chief Andrew Joe

https://www.fiercebiotech.com/biotech/european-cancer-biotech-merus-nabs-sanofi-i-o-chief-andrew-joe
👍️0

Your Recent History

NASDAQ
MRUS
Merus NV
Delayed Upgrade Clock
ADVFN Logo

United States
Company
Business
Popular
Get The App

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved